Web Results

en.wikipedia.org/wiki/Bruesewitz_v._Wyeth

Bruesewitz v. Wyeth, 562 U.S. 223 (2011), is a United States Supreme Court case that decided whether a section of the National Childhood Vaccine Injury Act of 1986 preempts all vaccine design defect claims against vaccine manufacturers . Contents. [hide]. 1 Background; 2 Decision; 3 See also; 4 References; 5 External ...

caselaw.findlaw.com/us-supreme-court/09-152.html

BRUESEWITZ ET AL. v. WYETH LLC, FKA WYETH, INC., ET AL., (2011). No. 09- 152. Argued: October 12, 2010 Decided: February 22, 2011. The National Childhood Vaccine Injury Act of 1986 (NCVIA or Act) created a no-fault compensation program to stabilize a vaccine market adversely affected by an increase in ...

www.oyez.org/cases/2010/09-152

Oct 12, 2010 ... Bruesewitz v. Wyeth Inc. ... Respondent. Wyeth, Inc., fka Wyeth Laboratories, et al . ... defective design. A federal judge dismissed the lawsuit, ruling that the National Childhood Vaccine Injury Act protected Wyeth from lawsuits over vaccine injury claims. The U.S. Court of Appeals for the 3rd Circuit affirmed.

citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.546.8632&rep=rep1&type=pdf

Pablo Avenue, Richmond, CA 94804; and Robert R. Ruffolo, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426. 0031-6997/02/5402- 219 –226 ... (Urade et al., 1994). This review reflects both peptide and nonpeptide ETB antagonists that are the com- pounds of choice. A second major change is the inclusion.

jpharmsci.org/article/S0022-3549(15)37870-9/fulltext

Journal of Pharmaceutical Sciences, pharmacokinetics, biopharmaceutics, pharmacodynamics, drug development, protein-peptide chemistry, drug delivery.

pharmrev.aspetjournals.org/content/54/2/219

Jun 1, 2002 ... Masaki et al. (1994) referred to a gene encoding a third receptor (P32940) cloned from the amphibian Xenopus laevis dermal melanophores, which was ..... The selectivity of ET-3 for ETB versus ETA receptors is often only about two orders and it is difficult to precisely delineate the two receptors using this ...

link.springer.com/content/pdf/10.1186/1476-5926-6-4.pdf

2007 Kelder et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

pubmedcentralcanada.ca/pmcc/ptpicrender.fcgi?aid=1445921&blobtype=html&lang=en-ca

We recently reported that Naked2 binds to these domains but not to TGFα's PDZ recognition domain (Li et al., 2004 blue right-pointing triangle ). Naked1 and .... The TACE/ADAM17 inhibitor WAY-022 was provided by Jay Gibbons (Wyeth Ayerst, Pearl River, NY). ...... v-SNAREs, and tethers to achieve vesicle fusion. In vitro ...

www.masstortdefense.com/tags/benzene

See, e.g., Kuhn v. Wyeth, Inc., 686 F.3d 618, 623–24 & 633 (8th Cir.2012) ( permitting testimony where the expert witness relied on methodologically reliable studies ..... Baker, et al. v. Chevron USA Inc., et al., No. 05-cv-00227 (S.D. Ohio Jan. 6, 2010). In the absence of necessary expert testimony, the claims were subject to ...